The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial
Open accessAbstract
Importance: There is limited evidence regarding early treatment of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to mitigate symptom progression. Objective: To examine whether high-dose zinc and/or high-dose ascorbic acid reduce the severity or duration of symptoms compared with usual care among ambulatory patients with SARS-CoV-2 infection. Design, Setting, and Participants: This multicenter, single health system randomized clinical factorial open-label trial enrolled 214 adult patients with a diagnosis of SARS-CoV-2 infection confirmed with a polymerase chain reaction assay who received outpatient care in sites in Ohio and Florida. The trial was conducted from April 27, 2020, to October 14, 2020. Intervention: Patients were randomized in a 1:1:1:1 allocation ratio to receive either 10 days of zinc gluconate (50 mg), ascorbic acid (8000 mg), both agents, or standard of care. Outcomes: The primary end point was the number of days required to reach a 50% reduction in symptoms, including severity of fever, cough, shortness of breath, and fatigue (rated on a 4-point scale for each symptom). Secondary end points included days required to reach a total symptom severity score of 0, cumulative severity score at day 5, hospitalizations, deaths, adjunctive prescribed medications, and adverse effects of the study supplements. Results: A total of 214 patients were randomized, with a mean (SD) age of 45.2 (14.6) years and 132 (61.7%) women. The study was stopped for a low conditional power for benefit with no significant difference among the 4 groups for the primary end point. Patients who received usual care without supplementation achieved a 50% reduction in symptoms at a mean (SD) of 6.7 (4.4) days compared with 5.5 (3.7) days for the ascorbic acid group, 5.9 (4.9) days for the zinc gluconate group, and 5.5 (3.4) days for the group receiving both (overall P = .45). There was no significant difference in secondary outcomes among the treatment groups. Conclusions and Relevance: In this randomized clinical trial of ambulatory patients diagnosed with SARS-CoV-2 infection, treatment with high-dose zinc gluconate, ascorbic acid, or a combination of the 2 supplements did not significantly decrease the duration of symptoms compared with standard of care. Trial Registration: ClinicalTrials.gov Identifier: NCT04342728.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Singh, M., & Das, R. R. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001364.pub4 · Cited by 237
RetractedSingh, M., & Das, R. R. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001364.pub3 · Cited by 86
RetractedClinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
te Velthuis, A. J. W., van den Worm, S. H. E., Sims, A. C., Baric, R. S., Snijder, E. J., & van Hemert, M. J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001176 · Cited by 893
Vitamin C for preventing and treating the common cold
Hemilä, H., & Chalker, E. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000980.pub4 · Cited by 869
Zinc in Infection and Inflammation
Gammoh, N., & Rink, L. (2017) · Nutrients · doi:10.3390/nu9060624 · Cited by 818
Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results
Meltzer, D. O., Best, T. J., Zhang, H., Vokes, T., Arora, V., & Solway, J. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.19722 · Cited by 510
Hemilä, H. (2017) · Nutrients · doi:10.3390/nu9040339 · Cited by 461
Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study
Eby, G. A., Davis, D. R., & Halcomb, W. W. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.25.1.20 · Cited by 217
Antiviral Activity of the Zinc Ionophores Pyrithione and Hinokitiol against Picornavirus Infections
Krenn, B. M., Gaudernak, E., Holzer, B., Lanke, K., Van Kuppeveld, F. J. M., & Seipelt, J. (2009) · Journal of Virology · doi:10.1128/jvi.01543-08 · Cited by 162
Hemilä, H. (2017) · JRSM Open · doi:10.1177/2054270417694291 · Cited by 145
Zinc gluconate lozenges for common cold. A double-blind clinical trial
Weismann, K., Jakobsen, J.-E., Weismann, J. E., Hammer, U., Nyholm, S., Hansen, B., Lomholt, K. E., & Schmidt, K. (1990) · PubMed · doi:10.5281/zenodo.11544824 · Cited by 70
Vitamin C, respiratory infections and the immune system
Hemilä, H. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.09.004 · Cited by 43
Vitamin C administration in the critically ill: a summary of recent meta-analyses
Carr, A. (2019) · Critical Care · doi:10.1186/s13054-019-2538-y · Cited by 31
Ascorbic acid and infectious bronchitis infections in broilers
Davelaar, F. G., & van den Bos, J. (1992) · Avian Pathology · doi:10.1080/03079459208418879 · Cited by 28
Cited by
Drug treatments for covid-19: living systematic review and network meta-analysis
Siemieniuk, R. A., Bartoszko, J. J., Zeraatkar, D., Kum, E., Qasim, A., Díaz Martinez, J. P., Izcovich, A., Rochwerg, B., Lamontagne, F., Han, M. A., et al. (2020) · BMJ · doi:10.1136/bmj.m2980 · Cited by 846
Prophylaxis against covid-19: living systematic review and network meta-analysis
Bartoszko, J. J., Siemieniuk, R. A., Kum, E., Qasim, A., Zeraatkar, D., Martinez, J. P. D., Azab, M., Ibrahim, S., Izcovich, A., Soto, G. B., et al. (2021) · BMJ · doi:10.1136/bmj.n949 · Cited by 113
Vlieg‐ Boerstra, B., de Jong, N., Meyer, R., Agostoni, C., De Cosmi, V., Grimshaw, K., Milani, G. P., Muraro, A., Oude Elberink, H., Pali‐ Schöll, I., et al. (2022) · Allergy · doi:10.1111/all.15136 · Cited by 75
Sinopoli, A., Sciurti, A., Isonne, C., Santoro, M. M., & Baccolini, V. (2024) · Nutrients · doi:10.3390/nu16091345 · Cited by 40
Metadata
- Authors
- Thomas, S., Patel, D., Bittel, B., Wolski, K., Wang, Q., Kumar, A., Il’Giovine, Z. J., Mehra, R., McWilliams, C., Nissen, S. E., & Desai, M. Y.
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2021-02-12
- Volume
- 4
- Issue
- 2
- Pages
- e210369
- ISSN
- 2574-3805 (ISSN-L)
- OpenAlex
- W3129183114
- Cited by
- 344
- References
- 17
- FWCI
- 23.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.